97920-04-2

Basic information

• Product Name: (±)-2,2'-((1S,2R)-cyclohexan-1,2-diyl)diacetonitrile
• Synonyms: (±)-2,2'-((1S,2R)-cyclohexan-1,2-diyl)diacetonitrile
• CAS NO: 97920-04-2
• Molecular Weight: 162.235
• Mol File: 97920-04-2.mol

Chemical Properties

• CAS DataBase Reference: (±)-2,2'-((1S,2R)-cyclohexan-1,2-diyl)diacetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (±)-2,2'-((1S,2R)-cyclohexan-1,2-diyl)diacetonitrile(97920-04-2)
• EPA Substance Registry System: (±)-2,2'-((1S,2R)-cyclohexan-1,2-diyl)diacetonitrile(97920-04-2)

Safety Data

• Hazardous Substances Data: 97920-04-2(Hazardous Substances Data)

Upstream product

• 66347-68-0 (±)-(1S, 2S)-cyclohexane-1,2-dimethanol bis(methanesulfonate) 
• 76155-27-6 (+/-)-trans-2-(hydroxymethyl)cyclohexylmethanol 
• 3205-36-5 trans-1,2-bis(hydroxymethyl)cyclohexane di-p-toluene-sulfonate 
• 15753-50-1 cis-1,2-cyclohexanedimethanol 
• 66347-68-0 (±)-(1S, 2R)-cyclohexane-1,2-dimethanol bis(methanesulfonate) 
• 59461-66-4 cis-cyclohexane-1,2-diyldimethyl ditosylate 
• 151-50-8 potassium cyanide 

Downstream Products

• 13553-40-7 cis-2,2'-(cyclohexane-1,2-diyl)diacetic acid 
• 40599-78-8 trans-cyclohexane-1,2-diacetic acid 
• 959009-59-7 (3aS,7aR)-2-Amino-3a,4,5,6,7,7a-hexahydro-3H-indene-1-carbonitrile 
• 866848-51-3 cis-(2-methoxycarbonylmethylcyclohexyl)acetic acid methyl ester 
• 97919-92-1 (R)-3-{2-[(1R,2S)-2-(2-Oxo-2-piperidin-1-yl-ethyl)-cyclohexyl]-acetyl}-2-thioxo-thiazolidine-4-carboxylic acid methyl ester 
• 97995-48-7 (R)-3-{2-[(1S,2R)-2-(2-Oxo-2-piperidin-1-yl-ethyl)-cyclohexyl]-acetyl}-2-thioxo-thiazolidine-4-carboxylic acid methyl ester 
• 97919-93-2 N-Benzyl-N-methyl-2-[(1R,2S)-2-(2-oxo-2-piperidin-1-yl-ethyl)-cyclohexyl]-acetamide 
• 97919-91-0 C₂₀H₂₆N₂O₆S₄ 

Relevant articles and documents

Discovery of octahydroindenes as PAR1 antagonists

Octahydroindene was identified as a novel scaffold for protease activated receptor 1 (PAR1) antagonists. Herein, the 2-position (C2) was explored for structure-activity relationship (SAR) studies. Compounds 14, 19, and 23b showed IC50 values of 1.3, 8.6, and 2.7 nM in a PAR1 radioligand binding assay, respectively, and their inhibitory activities on platelet activation were comparable to that of vorapaxar in a platelet rich plasma (PRP) aggregation assay. This series of compounds showed high potency and no significant cytotoxicity; however, the compounds were metabolically unstable in both human and rat liver microsomes. Current research efforts are focused on optimizing the compounds to improve metabolic stability and physicochemical properties as well as potency.

[6+5] FUSED BICYCLES AS A THROMBIN ANTAGONIST, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE BICYCLES

The present invention relates to the new [6+5] fused bicycle derivatives, pharmaceutically acceptable salts or isomers thereof, processes for preparing the same, and pharmaceutical compositions comprising the same. The [6+5] fused bicycle derivatives can antagonize the thrombin receptor and thus may be effectively used for the treatment and prevention of thrombus, platelet aggregation, atherosclerosis, restenosis, blood coagulation, hypertension, arrhythmia, angina pectoris, heart failure, inflammation and cancer when used alone or with other cardiovascular agents.